REPLIMUNE GROUP INC (REPL)
US76029N1063 - Common Stock
REPL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. REPL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. REPL has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year REPL has reported negative net income.
In the past year REPL has reported a negative cash flow from operations.
REPL had negative earnings in each of the past 5 years.
In the past 5 years REPL always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -42.76%, REPL is in line with its industry, outperforming 53.74% of the companies in the same industry.
The Return On Equity of REPL (-55.84%) is better than 63.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.76% | ||
| ROE | -55.84% | ||
| ROIC | N/A |
ROA(3y)-32.26%
ROA(5y)-26.83%
ROE(3y)-39.24%
ROE(5y)-32.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for REPL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for REPL has been increased compared to 1 year ago.
Compared to 5 years ago, REPL has more shares outstanding
Compared to 1 year ago, REPL has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.09 indicates that REPL is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.09, REPL is in the better half of the industry, outperforming 72.06% of the companies in the same industry.
REPL has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of REPL (0.18) is worse than 68.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.09 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 10.11 indicates that REPL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 10.11, REPL belongs to the top of the industry, outperforming 81.32% of the companies in the same industry.
REPL has a Quick Ratio of 10.11. This indicates that REPL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 10.11, REPL belongs to the top of the industry, outperforming 81.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.11 | ||
| Quick Ratio | 10.11 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 0.97% over the past year.
EPS 1Y (TTM)0.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, REPL will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.03% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.74%
EPS Next 2Y8.78%
EPS Next 3Y10.45%
EPS Next 5Y17.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
REPL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year REPL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.78%
EPS Next 3Y10.45%
5. Dividend
5.1 Amount
No dividends for REPL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REPLIMUNE GROUP INC
NASDAQ:REPL (12/20/2024, 8:00:01 PM)
After market: 12.49 0 (0%)12.49
+0.48 (+4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.17%
Inst Owner Change-0.92%
Ins Owners4.94%
Ins Owner Change-0.38%
Market Cap960.86M
Analysts85.71
Price Target16.83 (34.75%)
Short Float %7.7%
Short Ratio7.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.55%
Min EPS beat(2)10.17%
Max EPS beat(2)12.93%
EPS beat(4)3
Avg EPS beat(4)10.07%
Min EPS beat(4)-1.44%
Max EPS beat(4)18.62%
EPS beat(8)5
Avg EPS beat(8)6.59%
EPS beat(12)7
Avg EPS beat(12)3.11%
EPS beat(16)9
Avg EPS beat(16)1.76%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.94%
PT rev (3m)12.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.02%
EPS NY rev (1m)4.54%
EPS NY rev (3m)7.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)180.95%
Revenue NY rev (3m)210.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.52 | ||
| P/tB | 2.52 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.05
EYN/A
EPS(NY)-2.65
Fwd EYN/A
FCF(TTM)-2.45
FCFYN/A
OCF(TTM)-2.35
OCFYN/A
SpS0
BVpS4.96
TBVpS4.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.76% | ||
| ROE | -55.84% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-32.26%
ROA(5y)-26.83%
ROE(3y)-39.24%
ROE(5y)-32.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 237.65% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.11 | ||
| Quick Ratio | 10.11 | ||
| Altman-Z | 2.09 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)138.25%
Cap/Depr(5y)357.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.44%
EPS Next Y9.74%
EPS Next 2Y8.78%
EPS Next 3Y10.45%
EPS Next 5Y17.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.1%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-70.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.35%
OCF growth 3YN/A
OCF growth 5YN/A